Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity

Huntington's disease (HD) patients and mouse models show learning and memory impairment even before the onset of motor symptoms. Deficits in hippocampal synaptic plasticity have been involved in the HD memory impairment. Several studies show that prostaglandin E2 (PGE2) EP2 receptor stimulates...

Full description

Bibliographic Details
Main Authors: Marta Anglada-Huguet, Laura Vidal-Sancho, Albert Giralt, Gerardo García-Díaz Barriga, Xavier Xifró, Jordi Alberch
Format: Article
Language:English
Published: Elsevier 2016-11-01
Series:Neurobiology of Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996115300474
id doaj-cb2389e17973429a90512f8b43474e9a
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Marta Anglada-Huguet
Laura Vidal-Sancho
Albert Giralt
Gerardo García-Díaz Barriga
Xavier Xifró
Jordi Alberch
spellingShingle Marta Anglada-Huguet
Laura Vidal-Sancho
Albert Giralt
Gerardo García-Díaz Barriga
Xavier Xifró
Jordi Alberch
Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
Neurobiology of Disease
Hippocampus,
Huntingtin,
Misoprostol,
PSD-95
author_facet Marta Anglada-Huguet
Laura Vidal-Sancho
Albert Giralt
Gerardo García-Díaz Barriga
Xavier Xifró
Jordi Alberch
author_sort Marta Anglada-Huguet
title Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
title_short Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
title_full Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
title_fullStr Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
title_full_unstemmed Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
title_sort prostaglandin e2 ep2 activation reduces memory decline in r6/1 mouse model of huntington's disease by the induction of bdnf-dependent synaptic plasticity
publisher Elsevier
series Neurobiology of Disease
issn 1095-953X
publishDate 2016-11-01
description Huntington's disease (HD) patients and mouse models show learning and memory impairment even before the onset of motor symptoms. Deficits in hippocampal synaptic plasticity have been involved in the HD memory impairment. Several studies show that prostaglandin E2 (PGE2) EP2 receptor stimulates synaptic plasticity and memory formation. However, this role was not explored in neurodegenerative diseases. Here, we investigated the capacity of PGE2 EP2 receptor to promote synaptic plasticity and memory improvements in a model of HD, the R6/1 mice, by administration of the agonist misoprostol. We found that misoprostol increases dendritic branching in cultured hippocampal neurons in a brain-derived neurotrophic factor (BDNF)-dependent manner. Then, we implanted an osmotic mini-pump system to chronically administrate misoprostol to R6/1 mice from 14 to 18 weeks of age. We observed that misoprostol treatment ameliorates the R6/1 long-term memory deficits as analyzed by the T-maze spontaneous alternation task and the novel object recognition test. Importantly, administration of misoprostol promoted the expression of hippocampal BDNF. Moreover, the treatment with misoprostol in R6/1 mice blocked the reduction in the number of PSD-95 and VGluT-1 positive particles observed in hippocampus of vehicle-R6/1 mice. In addition, we observed an increase of cAMP levels in the dentate ` of WT and R6/1 mice treated with misoprostol. Accordingly, we showed a reduction in the number of mutant huntingtin nuclear inclusions in the dentate gyrus of R6/1 mice. Altogether, these results suggest a putative therapeutic effect of PGE2 EP2 receptor in reducing cognitive deficits in HD.
topic Hippocampus,
Huntingtin,
Misoprostol,
PSD-95
url http://www.sciencedirect.com/science/article/pii/S0969996115300474
work_keys_str_mv AT martaangladahuguet prostaglandine2ep2activationreducesmemorydeclineinr61mousemodelofhuntingtonsdiseasebytheinductionofbdnfdependentsynapticplasticity
AT lauravidalsancho prostaglandine2ep2activationreducesmemorydeclineinr61mousemodelofhuntingtonsdiseasebytheinductionofbdnfdependentsynapticplasticity
AT albertgiralt prostaglandine2ep2activationreducesmemorydeclineinr61mousemodelofhuntingtonsdiseasebytheinductionofbdnfdependentsynapticplasticity
AT gerardogarciadiazbarriga prostaglandine2ep2activationreducesmemorydeclineinr61mousemodelofhuntingtonsdiseasebytheinductionofbdnfdependentsynapticplasticity
AT xavierxifro prostaglandine2ep2activationreducesmemorydeclineinr61mousemodelofhuntingtonsdiseasebytheinductionofbdnfdependentsynapticplasticity
AT jordialberch prostaglandine2ep2activationreducesmemorydeclineinr61mousemodelofhuntingtonsdiseasebytheinductionofbdnfdependentsynapticplasticity
_version_ 1724208170650304512
spelling doaj-cb2389e17973429a90512f8b43474e9a2021-03-22T12:43:30ZengElsevierNeurobiology of Disease1095-953X2016-11-01952234Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticityMarta Anglada-Huguet0Laura Vidal-Sancho1Albert Giralt2Gerardo García-Díaz Barriga3Xavier Xifró4Jordi Alberch5Departament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Casanova, 143, 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Casanova, 143, 08036 Barcelona, SpainDepartament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Casanova, 143, 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Casanova, 143, 08036 Barcelona, Spain; New Therapeutic Targets Group (TargetsLab), Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, c/ Emili Grahit, 77, 17071 Girona, SpainDepartament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Casanova, 143, 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Casanova, 143, 08036 Barcelona, SpainDepartament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Casanova, 143, 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Casanova, 143, 08036 Barcelona, SpainDepartament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Casanova, 143, 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Casanova, 143, 08036 Barcelona, Spain; New Therapeutic Targets Group (TargetsLab), Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, c/ Emili Grahit, 77, 17071 Girona, SpainDepartament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Casanova, 143, 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Casanova, 143, 08036 Barcelona, Spain; Corresponding author at: Departament de Biologia Cellular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, C/ Casanova, 143, 08036 Barcelona, Spain.Huntington's disease (HD) patients and mouse models show learning and memory impairment even before the onset of motor symptoms. Deficits in hippocampal synaptic plasticity have been involved in the HD memory impairment. Several studies show that prostaglandin E2 (PGE2) EP2 receptor stimulates synaptic plasticity and memory formation. However, this role was not explored in neurodegenerative diseases. Here, we investigated the capacity of PGE2 EP2 receptor to promote synaptic plasticity and memory improvements in a model of HD, the R6/1 mice, by administration of the agonist misoprostol. We found that misoprostol increases dendritic branching in cultured hippocampal neurons in a brain-derived neurotrophic factor (BDNF)-dependent manner. Then, we implanted an osmotic mini-pump system to chronically administrate misoprostol to R6/1 mice from 14 to 18 weeks of age. We observed that misoprostol treatment ameliorates the R6/1 long-term memory deficits as analyzed by the T-maze spontaneous alternation task and the novel object recognition test. Importantly, administration of misoprostol promoted the expression of hippocampal BDNF. Moreover, the treatment with misoprostol in R6/1 mice blocked the reduction in the number of PSD-95 and VGluT-1 positive particles observed in hippocampus of vehicle-R6/1 mice. In addition, we observed an increase of cAMP levels in the dentate ` of WT and R6/1 mice treated with misoprostol. Accordingly, we showed a reduction in the number of mutant huntingtin nuclear inclusions in the dentate gyrus of R6/1 mice. Altogether, these results suggest a putative therapeutic effect of PGE2 EP2 receptor in reducing cognitive deficits in HD.http://www.sciencedirect.com/science/article/pii/S0969996115300474Hippocampus,Huntingtin,Misoprostol,PSD-95